Loading…
Humacyte, Inc. is projected to rise to $0.6606 by 2027, a +1% move from its current price of $0.6534. HUMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $0.6207 | $0.653 | $0.6871 | -0.06% |
| Aug 5 | $0.6074 | $0.6527 | $0.7013 | -0.11% |
| Aug 6 | $0.5973 | $0.6523 | $0.7124 | -0.17% |
| Aug 7 | $0.5889 | $0.652 | $0.7217 | -0.22% |
| Aug 8 | $0.5816 | $0.6516 | $0.73 | -0.28% |
| Aug 9 | $0.575 | $0.6512 | $0.7376 | -0.33% |
| Aug 10 | $0.569 | $0.6509 | $0.7446 | -0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.569 | $0.6509 | $0.7446 | -0.39% |
| Week 2 | $0.536 | $0.6484 | $0.7842 | -0.77% |
| Week 3 | $0.5116 | $0.6458 | $0.8153 | -1.16% |
| Week 4 | $0.4916 | $0.6433 | $0.8419 | -1.54% |
| Week 5 | $0.4744 | $0.6409 | $0.8657 | -1.92% |
| Week 6 | $0.4592 | $0.6384 | $0.8875 | -2.30% |
| Week 7 | $0.4455 | $0.6359 | $0.9077 | -2.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Humacyte, Inc. (HUMA) trades at $0.6446 per share and has a market capitalization of $173.81M, ranking 3746 by market cap. The current price is complemented by a 30-day price action range and a set of technical indicators that frame its near-term trajectory.
A major floor 34.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.1% below — buyers have tended to step in here.
The nearest ceiling, 41.4% above — a clean break opens room to run.
A major ceiling 128.0% above — clearing it would confirm fresh momentum.
Key HUMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HUMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.651 | Buy | $0.6512 | Buy |
| MA 10 | $0.6491 | Buy | $0.6564 | Sell |
| MA 20 | $0.6783 | Sell | $0.6927 | Sell |
| MA 50 | $0.9048 | Sell | $0.80 | Sell |
| MA 100 | $0.8721 | Sell | $0.8988 | Sell |
| MA 200 | $1.05 | Sell | $1.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.74 | Neutral |
| Stoch RSI (14) | 79.29 | Neutral |
| CCI (20) | -52.12 | Neutral |
| Williams %R (14) | -65.85 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -4.25 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 34.15 | Neutral |
| TRIX (15) | -1.36 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 48.12 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 0.65 | Buy |
| ADX (14) | 23.13 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture presents a neutral momentum with RSI(14) at 40. The 50-day simple moving average is $0.9482 and the 200-day simple moving average is $1.09, signaling potential resistance ahead of the longer-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.575 | $0.6534 | $0.7929 | 0% | Neutral | |
| $0.4858 | $0.6606 | $0.9697 | +1% | Neutral | |
| $0.3793 | $0.5467 | $0.8542 | -16% | Bearish | |
| $0.3285 | $0.4973 | $0.8149 | -24% | Bearish | |
| $0.4408 | $0.6976 | $1.19 | +7% | Neutral | |
| $0.4746 | $0.7828 | $1.38 | +20% | Neutral | |
| $0.48 | $0.8235 | $1.50 | +26% | Bullish | |
| $0.4501 | $0.8018 | $1.50 | +23% | Bullish | |
| $0.3585 | $0.6625 | $1.27 | +1% | Neutral | |
| $0.3986 | $0.7633 | $1.49 | +17% | Neutral | |
| $0.4384 | $0.9742 | $2.09 | +49% | Bullish | |
| $0.9021 | $2.00 | $4.61 | +207% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.575 | $0.6534 | $0.7682 | +0.00% |
| September 2026 | $0.5211 | $0.632 | $0.7987 | -3.28% |
| October 2026 | $0.5056 | $0.6212 | $0.8004 | -1.70% |
| November 2026 | $0.4724 | $0.5868 | $0.7677 | -5.55% |
| December 2026 | $0.4765 | $0.5978 | $0.7929 | +1.88% |
Click any year to see its month-by-month HUMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HUMA price prediction for 2026 points to an average of $0.6534 (low $0.575, high $0.7929) — a potential gain of 0% on today's $0.6534. Price action looks broadly range-bound.
In 2027, HUMA is projected to trade between $0.4858 and $0.9697, averaging $0.6606 — a potential gain of +1% from today's $0.6534. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
Humacyte, Inc.'s 2028 outlook centres on $0.5467, within a $0.3793 to $0.8542 range. That is -17% versus the projected 2027 average. That marks a -16% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2029, HUMA could reach as high as $0.8149, with a base case around $0.4973 and support toward $0.3285 — roughly -24% from $0.6534. Expect choppier, lower action through this leg of the cycle.
Expect HUMA to range from $0.4408 to $1.19 through 2030. The $0.6976 average target implies a +7% move from current prices. That is up +40% on the projected 2029 average. Price action looks broadly range-bound.
The HUMA price prediction for 2031 points to an average of $0.7828 (low $0.4746, high $1.38) — a potential gain of +20% on today's $0.6534. A consolidation phase looks the most probable path here.
In 2032, HUMA is projected to trade between $0.48 and $1.50, averaging $0.8235 — a potential gain of +26% from today's $0.6534. That is up +5% on the projected 2031 average. Momentum favours further upside here.
Humacyte, Inc.'s 2033 outlook centres on $0.8018, within a $0.4501 to $1.50 range. That is -3% versus the projected 2032 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, HUMA could reach as high as $1.27, with a base case around $0.6625 and support toward $0.3585 — roughly +1% from $0.6534. Price action looks broadly range-bound.
Expect HUMA to range from $0.3986 to $1.49 through 2035. The $0.7633 average target implies a +17% move from current prices. That is up +15% on the projected 2034 average. A consolidation phase looks the most probable path here.
The HUMA price prediction for 2040 points to an average of $0.9742 (low $0.4384, high $2.09) — a potential gain of +49% on today's $0.6534. Momentum favours further upside here.
In 2050, HUMA is projected to trade between $0.9021 and $4.61, averaging $2.00 — a potential gain of +207% from today's $0.6534. That is up +106% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in HUMA today (≈ 1,530.456076 HUMA) could be worth
$3,067.98
+$2,067.98 (+207%) by 2050 · US Dollar
Based on the average projected HUMA price of $2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HUMAwould be worth at today's price.
$1,000 invested in HUMA on Jul 31, 2025 (≈ 416.66665 HUMA) would be worth
$272.25
-$727.75 (-72.8%) today · 0.27× · US Dollar
Based on a HUMA entry price of $2.4 vs. today's $0.6534.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.625 | $1,045.44 | +4.5% |
| 1 month ago | $0.673 | $970.88 | -2.9% |
| 3 months ago | $0.855 | $764.21 | -23.6% |
| 6 months ago | $1.02 | $640.59 | -35.9% |
| 1 year ago | $2.4 | $272.25 | -72.8% |
| All time (5.0y) ago | $10.01 | $65.27 | -93.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HUMA forecast.
Our base-case forecast reaches $1.30 around 2050.
Implied market cap at $1.30: $350.53M
The year-by-year forecast shows a mixed path: 2026 average price $0.6446 with a min of $0.575 and a max of $0.8074 (ROI 0), and sentiment NEUTRAL. Through the early years, several years exhibit negative ROI, such as 2028 (-21.4) and 2029 (-29.1), with sentiment BEARISH. The 2030 forecast shows an average of $0.6122 and ROI -5 (NEUTRAL), while 2031 and 2032 show improving momentum with averages of $0.6989 and $0.7588 and ROI 8.4 and 17.7, respectively.
The forecast indicates continued growth into 2040 (avg $0.8173, ROI 26.8; sentiment BULLISH) and 2050 (avg $1.76, ROI 172.3; sentiment BULLISH), with the max price reaching as high as $4.04 in 2050. Overall, the outlook shifts from neutral/bearish in the 2026–2035 window to bullish in 2040–2050, though these figures are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030, the average price is forecast at $0.6122, with a min of $0.379 and a max of $1.06; ROI is -5 and sentiment NEUTRAL.
The forecast shows mixed signals. The years 2026–2035 are Neutral to Bearish, with some negative ROI, while 2040 and 2050 are Bearish to Bullish with ROIs of 26.8 and 172.3 respectively, indicating potential upside later in the horizon but notable risk in earlier years.
Yes. The year-by-year forecast shows max prices above $1 in several years: 2032 max $1.40, 2033 max $1.37, 2034 max $1.13, 2035 max $1.35, 2040 max $1.79, and 2050 max $4.04.
The 30-day range is from $0.4478 to $0.928.
Humacyte, Inc. Community Discussion
0Share your Humacyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.